The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features the return of Mark Selby, CEO and Director of Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF), a company working to advance the next generation of high quality nickel sulphide projects to feed the high growth electric vehicle and stainless steel markets.

To begin the interview, Selby discussed the company’s recent news release announcing the positive Bankable Feasibility Study for its Crawford Nickel Sulphide Project.

“It’s a major milestone for the company – $2.5 billion after-tax NPV, 17% IRR. When you include the additional carbon capture and storage tax credits that we think we’ll be able to get, that nudges the IRR up to 18%. This is for a project that’s going to be a 40-year mine life,” Selby said. “We’re the second-largest nickel reserve in the world, the second-largest nickel resource in the world and, if we were fully ramped-up today, we’d be the third-largest nickel-sulphide operation globally.”

“This is in a nickel market where more than 100% of the supply has effectively come from Chinese-controlled sources in Indonesia, most of which with a massive carbon footprint. Because of the host rock we have, in addition to producing all that nickel, as well as cobalt, palladium, platinum, iron and chrome, we will also have the ability to store 1.5 million tons of CO², which would also make us one of the largest carbon storage facilities in the world. If you look at what our overall effective carbon footprint would be, it would be negative 30 tons of CO². So, in today’s world where everyone is looking for low-carbon alternatives, we’re a negative carbon alternative in terms of nickel production.”

Selby then turned his attention toward recent updates relating to Canada Nickel Company’s other projects.

“Crawford is just the first project of what we think is an entire nickel district in Timmins, which is a very established mining camp with all the major infrastructure in place. We assembled a package of 20 different properties, each of which we believe has an ultramafic deposit. We’ve successfully tested nine of them; three of them have a larger target footprint than what we have with Crawford. We’ve been very happy with those results.”

Join IBN’s Stuart Smith and Mark Selby, CEO and Director of Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF), to learn more about the company’s recent milestones relating to the Crawford project and the development of its IPT Carbonation process, as well as its goals for the balance of 2023 and beyond.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

Bell2Bell’s latest podcast features the return of Mark Selby, CEO and Director of Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF), a company working to advance the next generation of high quality nickel sulphide projects to feed the high growth electric vehicle and stainless steel markets.

To begin the interview, Selby discussed the company’s recent news release announcing the positive Bankable Feasibility Study for its Crawford Nickel Sulphide Project.

“It’s a major milestone for the company – $2.5 billion after-tax NPV, 17% IRR. When you include the additional carbon capture and storage tax credits that we think we’ll be able to get, that nudges the IRR up to 18%. This is for a project that’s going to be a 40-year mine life,” Selby said. “We’re the second-largest nickel reserve in the world, the second-largest nickel resource in the world and, if we were fully ramped-up today, we’d be the third-largest nickel-sulphide operation globally.”

“This is in a nickel market where more than 100% of the supply has effectively come from Chinese-controlled sources in Indonesia, most of which with a massive carbon footprint. Because of the host rock we have, in addition to producing all that nickel, as well as cobalt, palladium, platinum, iron and chrome, we will also have the ability to store 1.5 million tons of CO², which would also make us one of the largest carbon storage facilities in the world. If you look at what our overall effective carbon footprint would be, it would be negative 30 tons of CO². So, in today’s world where everyone is looking for low-carbon alternatives, we’re a negative carbon alternative in terms of nickel production.”

Selby then turned his attention toward recent updates relating to Canada Nickel Company’s other projects.

“Crawford is just the first project of what we think is an entire nickel district in Timmins, which is a very established mining camp with all the major infrastructure in place. We assembled a package of 20 different properties, each of which we believe has an ultramafic deposit. We’ve successfully tested nine of them; three of them have a larger target footprint than what we have with Crawford. We’ve been very happy with those results.”

Join IBN’s Stuart Smith and Mark Selby, CEO and Director of Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF), to learn more about the company’s recent milestones relating to the Crawford project and the development of its IPT Carbonation process, as well as its goals for the balance of 2023 and beyond.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

Bell2Bell’s latest podcast features the return of Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production.

To begin the interview, Clowater expounded on a recent news release detailing why the company’s management team feels GEMXX is currently undervalued.

“Since its inception, GEMXX has always looked for resource assets that are commercially viable. To date, we’ve acquired five properties, but only one of those properties has a partial assessment known as an S-K 1300, which is a report produced by a qualified professional,” Clowater explained. “These reports offer comprehensive insights into mineral resources, reserves, exploration, outcome and the technical intricacies of a project. That being said, the report is not required to determine if a property is a good acquisition – if you have enough mining experience.”

Bell2Bell’s latest podcast features the return of Richard Clowater, President of GEMXX Corp. (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production.

To begin the interview, Clowater expounded on a recent news release detailing why the company’s management team feels GEMXX is currently undervalued.

“Since its inception, GEMXX has always looked for resource assets that are commercially viable. To date, we’ve acquired five properties, but only one of those properties has a partial assessment known as an S-K 1300, which is a report produced by a qualified professional,” Clowater explained. “These reports offer comprehensive insights into mineral resources, reserves, exploration, outcome and the technical intricacies of a project. That being said, the report is not required to determine if a property is a good acquisition – if you have enough mining experience.”

Bell2Bell’s latest podcast features Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD), along with Buzz Woods from Corporate Communications, who join the podcast to share insights into the biopharmaceutical company's groundbreaking work in novel anti-purinergic drug therapies (APT) for neurologic conditions, primarily Autism Spectrum Disorder (ASD).

Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm, provides valuable perspectives on its innovative initiatives and visionary advancements in the sphere of novel anti-purinergic drug therapies. Gain an exclusive understanding of PaxMedica's pioneering efforts in neurology and biopharmaceutical breakthroughs, with a special emphasis on advancements in treating Autism Spectrum Disorder (ASD) and other neurologic conditions, as Howard Weisman, Chairman and CEO, and Buzz Woods from Corporate Communications, offer a compelling overview of the company's recent achievements and future objectives.

Join the highly acclaimed host, Bell2Bell's Stuart Smith, and Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD) and Buzz Woods Corporate Communications, to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

This episode was recorded live at the venue hosting the 2023 American Association for Cancer Research Conference for Molecular Targets and Cancer Therapeutics, one of the premier conferences in the field. The conference serves as a platform for researchers, clinicians, and industry professionals to present and discuss the latest breakthroughs in cancer research.

Dr. Berger provided valuable insights into Genprex's recent groundbreaking achievements, particularly focusing on the promising data presented at the conference. He delved into the positive implications of the Acclaim-1 Phase 1 study, shedding light on the absence of Dose Limiting Toxicity and the potential impact of REQORSA® in the treatment of non-small cell lung cancer (NSCLC). Additionally, he discussed the upcoming Acclaim-3 clinical trial and the preclinical data in small cell lung cancer (SCLC), highlighting its significance in advancing SCLC treatment.

To gain a comprehensive understanding of Genprex's recent milestones and its transformative impact on cancer treatment, be sure to tune in to this informative episode.

Bell2Bell’s latest podcast features Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD), along with Buzz Woods from Corporate Communications, who join the podcast to share insights into the biopharmaceutical company's groundbreaking work in novel anti-purinergic drug therapies (APT) for neurologic conditions, primarily Autism Spectrum Disorder (ASD).

Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm, provides valuable perspectives on its innovative initiatives and visionary advancements in the sphere of novel anti-purinergic drug therapies. Gain an exclusive understanding of PaxMedica's pioneering efforts in neurology and biopharmaceutical breakthroughs, with a special emphasis on advancements in treating Autism Spectrum Disorder (ASD) and other neurologic conditions, as Howard Weisman, Chairman and CEO, and Buzz Woods from Corporate Communications, offer a compelling overview of the company's recent achievements and future objectives.

Join the highly acclaimed host, Bell2Bell's Stuart Smith, and Howard Weisman, Chairman and CEO of PaxMedica, Inc. (Nasdaq: PXMD) and Buzz Woods Corporate Communications, to learn more about the company’s recent milestones and operational goals for the balance of 2023 and beyond.

Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.

This episode was recorded live at the venue hosting the 2023 American Association for Cancer Research Conference for Molecular Targets and Cancer Therapeutics, one of the premier conferences in the field. The conference serves as a platform for researchers, clinicians, and industry professionals to present and discuss the latest breakthroughs in cancer research.

Dr. Berger provided valuable insights into Genprex's recent groundbreaking achievements, particularly focusing on the promising data presented at the conference. He delved into the positive implications of the Acclaim-1 Phase 1 study, shedding light on the absence of Dose Limiting Toxicity and the potential impact of REQORSA® in the treatment of non-small cell lung cancer (NSCLC). Additionally, he discussed the upcoming Acclaim-3 clinical trial and the preclinical data in small cell lung cancer (SCLC), highlighting its significance in advancing SCLC treatment.

To gain a comprehensive understanding of Genprex's recent milestones and its transformative impact on cancer treatment, be sure to tune in to this informative episode.

Bell2Bell’s latest podcast features Rob Etherington, President and CEO of Clene Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington provided an introduction to Clene’s business model and discussed recent developments providing hope to those affected by neurodegenerative conditions.

“Clene spends every waking moment working on amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative condition. We are focused on neurodegenerative diseases generally – including multiple sclerosis and Parkinson’s – but our body of evidence that has really come to the forefront in the last few years has been all around ALS,” Etherington explained. “The timing is important because this remains a remarkably devastating disease with life mortality of 3-5 years from diagnosis. It remains uniformly and universally fatal… It’s just devastating and tragic.”

Bell2Bell’s latest podcast features Rob Etherington, President and CEO of Clene Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington provided an introduction to Clene’s business model and discussed recent developments providing hope to those affected by neurodegenerative conditions.

“Clene spends every waking moment working on amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative condition. We are focused on neurodegenerative diseases generally – including multiple sclerosis and Parkinson’s – but our body of evidence that has really come to the forefront in the last few years has been all around ALS,” Etherington explained. “The timing is important because this remains a remarkably devastating disease with life mortality of 3-5 years from diagnosis. It remains uniformly and universally fatal… It’s just devastating and tragic.”